 Source: shutterstock.comAnastasia Zagoruyko Longeveron NASDAQ: LGVN stock is on the move Wednesday after the FDA granted its fast-track designation for Lomecel-B. Lomecel-B is a allogeneic, bone marrow-derived medicinal signaling cell MSC product in development to treat Hypoplastic Left Heart Syndrome HLHS in infants. 